In COVID-19 clinical update #76, Daniel Griffin covers association of age and pediatric household transmission, rapid antigen testing in remote communities, shedding of infectious virus in vaccinated individuals, FDA amendment of mRNA vaccine EUA to allow a third dose, new vaccine mandate for NY state, full vaccination suppresses selection of variants, effectiveness of mRNA vaccines in nursing homes, sustained effectiveness of mRNA vaccines against hospitalization, and no benefit from early convalescent serum in high-risk outpatients.
In COVID-19 clinical update #75, Daniel Griffin reviews vaccine effectiveness against transmission, modeling effectiveness of daily antigen tests, updated CDC guidance for fully vaccinated, risk of infection with time after mRNA vaccination, reduced risk of infection after vaccination, therapeutic anticoagulants in critically ill patients, and 6 month outcomes in hospitalized patients.
In COVID-19 clinical update #74, Daniel Griffin covers infections in vaccinated individuals, expansion of Regeneron monoclonal antibody cocktail for prophylaxis, neutralization of variants by antibodies produced by infection or vaccination, longer hospital stays associated with remdesivir treatment, and post-acute sequelae of infection and impact on quality of life 1-6 months after illness.
In COVID-19 clinical update #73, Daniel Griffin reviews updated mask guidance from CDC, infections in public school district employees, effectiveness of vaccines against delta variant, antibody response after third vaccine dose in kidney transplant recipients, protection afforded by mRNA vaccines fully vaccinated people with and without prior infections, correlates of protection in nonhuman primates, lack of effectiveness of doxycycline, neurological manifestations of COVID-19, and infection in vaccinated health care workers.
In this special episode, Daniel Griffin answers listener questions on COVID-19 vaccines, vaccine misinformation, long COVID, masking and distancing, school safety, and much more.
In COVID-19 clinical update #72, Daniel Griffin covers long term symptoms in children, outcomes for MIS-C, recent guidance from the American Academy of Pediatrics, a large well traced outbreak of delta variant, low dose mRNA vaccination generates durable T cell memory and antibodies, protective immunity in recovered patients, assessment of BinaxNOW, no effect of oral azithromycin, post-discharge symptoms in Nigeria, and therapeutics for low and middle income countries.
In COVID-19 clinical update #71, Daniel Griffin reviews updated school and child care guidance from CDC, transmission in schools, accuracy of lateral flow assays, update to J&J/Janssen vaccine EUA to include GBS, interim immunogenicity of Ad.26.CoV2.s, effectiveness of mRNA vaccines to prevent hospitalization, Bamlanivimab plus Etesevimab for mild or moderate disease, and a meta-analysis of ivermectin results.
In COVID-19 clinical update #70, Daniel Griffin discusses efficacy of portable air cleaners, vaccine induced serum neutralizing antibodies against variants, prevention and attenuation of disease with mRNA vaccines, ivermectin to prevent hospitalization, IL-6 antagonists and mortality, and impact of vaccination on long COVID.
In COVID-19 clinical update #69, Daniel Griffin covers effectiveness of mRNA vaccines against the delta variant, depression among public health workers, correlates of protection against asymptomatic and symptomatic infection, BNT162b2 in ChAdOx-1-S primed individuals, prior infection rescues B and T cell responses to variants after vaccination, effect of vaccination on household transmission, germinal responses induced by mRNA vaccines, phase 3 results of Novavax vaccine, and long COVID as our next national health disaster.
In COVID-19 clinical update #68, Daniel Griffin discusses children acquiring infection at birthday parties, immunogenicity of vaccines in solid organ transplant patients, reinfection rates in recovered patients, lack of efficacy of azithromycin, bacterial and fungal infections in hospitalized patients, effect of monoclonal antibody treatment on clinical outcomes of ambulatory patients, and reduction in mortality of hospitalized patients treated with remedesivir.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.